Jun Fang

TL;DR: Mangiferin is a novel Nrf2 activator that reduces oxidative stress and protects normal cells without reducing the sensitivity to etoposide of HL-60 leukemia cells in vitro and may be a potential chemotherapy adjuvant.

TL;DR: Evidence is provided that MA increases Nrf2 protein stability by inhibiting its ubiquitination and degradation in hematopoietic cells, which may be one of the mechanisms through which MA activates the NRF2-mediated antioxidant response and exerts cytoprotective effects.

TL;DR: Analysis of EMPs found that EMPs derived from TNF-α-stimulated human umbilical vein endothelial cells concentrated more microRNA-155 (miR-155) compared with maternal cells, which provides a mechanistic framework in which miR- 155 delivered by EMPs is involved in aGVHD pathogenesis by activating specific T lymphocytes functions.

TL;DR: In neuroblastoma cell lines overexpressed TF ligated with FVIIa produced upregulation of Bcl-2 expression through the JAK/STAT5 signaling pathway, resulting in resistance to apoptosis, surmise that this TF-FVIIa pathway may contribute, at least in part, to chemotherapy resistance in Neuroblastoma.

TL;DR: Data provide reinforcing evidence that the novel haplo-HSCT system could dramatically improve the survival of high-risk acute leukemia with low relapse and acceptable transplantation-related mortality, and might be a promising therapeutic option for high- risk patients.